Fri, Nov 22, 2024 | Jumada al-Awwal 21, 1446 | DXB ktweather icon0°C

Coronavirus: Abu Dhabi launches website for vaccine trial volunteers

Top Stories

Volunteers, Abu Dhabi, vaccine, trial, coronavirus, Covid-19, register, website

Abu Dhabi - People aged between 18 and 60 are eligible to take part as long as they haven't had Covid-19 and have a medical check-up.

Published: Fri 17 Jul 2020, 10:44 PM

Updated: Sat 18 Jul 2020, 8:59 AM

Volunteers in Abu Dhabi interested in participating in the world's first World Health Organization-enlisted global clinical Phase III trials of a Covid-19 inactivated vaccine can now register on www.4humanity.ae, officials announced on Thursday evening.
Volunteers need to submit their details and contact information to the organisers of this historic initiative.
Emiratis and residents of all nationalities aged between 18 and 60 are eligible to take part in the trials if considered suitable after a medical check-up.
A special hotline, 02 819 1111, has also been created for all volunteers signing up for the trials.

Officials said the target number of volunteers for the first stage of the trials in 5,000.
Those volunteering must live in Abu Dhabi and Al Ain. They should be in good health, not suffering from chronic illnesses and should have no history of Covid-19 infection.
Sheikh Abdullah bin Mohammed Al Hamed, Chairman of the Department of Health - Abu Dhabi was the first person given the Phase III inactivated vaccine for COVID-19.
 
The trials are the result of a partnership between Abu Dhabi based G42 Healthcare, currently at the forefront of the battle against Covid-19 in the UAE, and Sinopharm CNBG, the world's sixth largest vaccine manufacturer.

 
The trials are being operated by health practitioners from Abu Dhabi Health Services Company (Seha), who are operating facilities at five of their sites in Abu Dhabi and Al Ain in addition to a mobile clinic to ensure the trials are readily accessible to volunteers participating in the programme.
 
The UAE was the preferred choice to conduct the Phase III trials for the inactive Covid-19 vaccine because of its demographic heterogeneity, allowing for robust research across multiple ethnicities and increasing its feasibility for global application to the success of the trials. 
ismail@khaleejtimes.com 



Next Story